ONX 0912,
oprozomib,
Oprozomib,
935888-69-0,
ONX-0912,
ONX 0912,
Oprozomib (ONX-0912),
PR-047,
UNII-MZ37792Y8J,
MZ37792Y8J,
Oprozomib (ONX 0912),
N-((S)-3-methoxy-1-(((S)-3-methoxy-1-(((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)-2-methylthiazole-5-carboxamide,
Oprozomib [USAN:INN],
PR 047,
oprozomib-onx-0912,
Oprozomib (USAN/INN),
GTPL8739,
SCHEMBL1709971,
CHEMBL2103884,
C25H32N4O7S,
EX-A332,
ONX0912,
SWZXEVABPLUDIO-WSZYKNRRSA-N,
AOB87341,
BCP07603,
2614AH,
BDBM50398607,
MFCD25976563,
ZINC43202141,
AKOS028109171,
CS-2767,
DB11991,
QC-9273,
SB16496,
NCGC00345799-01,
AS-17020,
BC600600,
HY-12113,
O-Methyl-N-((2-methylthiazol-5-yl)carbonyl)-L-seryl-O-methyl-N-((1S)-1-benzyl-2-((2R)- 2-methyloxiran-2-yl)-2-oxoethyl)-L-serinamide,
FT-0700414,
A14181,
D10318,
S-7831,
J-690398,
L-Serinamide, O-methyl-N-((2-methyl-5-thiazolyl)carbonyl)-L-seryl-O-methyl-N-((1S)-2- ((2R)-2-methyl-2-oxiranyl)-2-oxo-1-(phenylmethyl)ethyl)-,
L-Serinamide, O-methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-,
L-Serinamide, O-methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-,
N-((S)-3-methoxy-1-((S)-3-methoxy-1-((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-ylamino)-1-oxopropan-2-ylamino)-1-oxopropan-2-yl)-2-methylthiazole-5-carboxamide,
N-?((S)?-?3-?methoxy-?1-?(((S)?-?3-?methoxy-?1-?(((S)?-?1-?((R)?-?2-?methyloxiran-?2-?yl)?-?1-?oxo-?3-?phenylpropan-?2-?yl)?amino)?-?1-?oxopropan-?2-?yl)?amino)?-?1-?oxopropan-?2-?yl)?-?2-?methylthiazole-?5-?carboxamide,
N-[(2S)-3-methoxy-1-[[(2S)-3-methoxy-1-[[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide,
PR-047|||ONX-0912|||N-[(2S)-3-Methoxy-1-[[(2S)-3-methoxy-1-[[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide,
1,2-Epoxyhexane,
Oprozomib [USAN],
D0F9BT,
PR-141,
PR-924,
PR-928,
ACN-039825,
A1934,
Proteasome inhibitor (oral, cancer), Proteolix Inc/Onyx Pharmaceuticals Inc,
Proteasome inhibitor program (oral, cancer), Onyx Pharmaceuticals/Ono Pharmaceutical,
O-Methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-L-serinamide,